ResearcherUniversity of AlabamaActive in the last 2 years

Sooryanarayana Varambally

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2277-1127; OpenAlex author ID A5079699559. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 3

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Upender Manne · 2 shared papers, 2020–2024 · strength 0.30
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
- Paper PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. DOI 10.1016/j.tranon.2020.100776 ↗
Sumit Agarwal · 2 shared papers, 2020–2024 · strength 0.30
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
- Paper PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. DOI 10.1016/j.tranon.2020.100776 ↗
Farrukh Afaq · 1 shared paper, 2024 · strength 0.20
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
Moh'd M. Khushman · 1 shared paper, 2024 · strength 0.20
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
Priyabrata Mukherjee · 1 shared paper, 2024 · strength 0.20
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
Subhash C. Chauhan · 1 shared paper, 2024 · strength 0.20
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
Donald J Buchsbaum · 1 shared paper, 2020 · strength 0.10
- Paper PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. DOI 10.1016/j.tranon.2020.100776 ↗
Isam‐Eldin A. Eltoum · 1 shared paper, 2020 · strength 0.10
- Paper PAICS, a De Novo Purine Biosynthetic Enzyme, Is Overexpressed in Pancreatic Cancer and Is Involved in Its Progression. DOI 10.1016/j.tranon.2020.100776 ↗
Karuna Mittal · 1 shared paper, 2015 · strength 0.06
- Paper Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma. DOI 10.1080/15384101.2015.1068478 ↗
Michelle Dian Reid · 1 shared paper, 2015 · strength 0.06
- Paper Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma. DOI 10.1080/15384101.2015.1068478 ↗
Ritu Aneja · 1 shared paper, 2015 · strength 0.06
- Paper Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma. DOI 10.1080/15384101.2015.1068478 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.